You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novartis
since
auto-detected in 23 stories
4 days ago
These are the stocks posting the largest moves in early trading.
89 days ago
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months' ⊖
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs ○
Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
3 months ago
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week ⊕
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
4 months ago
Henrietta Lacks: Family of woman whose cells were 'stolen' settles second lawsuit ○
Novartis is the second drug company to settle a lawsuit brought by the family of a woman whose cells have enabled huge advances in science.
Novartis, Genentech file suit alleging illegal importation of prescription drug ⊖
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.
6 months ago
Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC ⊖
The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries.
8 months ago
Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs ⊕
Novartis said its eight most promising approved drugs each carry peak-sales potential of $3 billion to $10 billion.
Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done' ○
Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.
Novartis set to buy Avidity Biosciences for more than $10bn ○
found
a story from Financial Times ✅ › Financial Times
Deal would be biggest acquisition under chief executive Vas Narasimhan